Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients

Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients

Strategies to address the challenges associated with product manufacturing can improve chimeric antigen receptor (CAR) cell–based therapeutics. Here the authors report the results of two clinical trials in patients with B-cell malignancies, showing that place-of-care manufacturing has a low producti...

Full description

Bibliographic Details
Main Authors: Michael Maschan, Paolo F. Caimi, Jane Reese-Koc, Gabriela Pacheco Sanchez, Ashish A. Sharma, Olga Molostova, Larisa Shelikhova, Dmitriy Pershin, Alexey Stepanov, Yakov Muzalevskii, Vinicius G. Suzart, Folashade Otegbeye, David Wald, Ying Xiong, Darong Wu, Adam Knight, Ibe Oparaocha, Beatrix Ferencz, Andre Roy, Andrew Worden, Winfried Kruger, Michael Kadan, Dina Schneider, Rimas Orentas, Rafick-Pierre Sekaly, Marcos de Lima, Boro Dropulić
Format: Article
Language:English
Published: Nature Portfolio 2021-12-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-27312-6

Internet

https://doi.org/10.1038/s41467-021-27312-6

Similar Items